<DOC>
	<DOCNO>NCT00719498</DOCNO>
	<brief_summary>The purpose study test possible neuroprotective effect early high dose erythropoietin alpha hospital cardiac arrest ( OHCA ) .</brief_summary>
	<brief_title>Effect Early High-dose Epoetin Alfa During Cardiac Arrest ( Pilot Study )</brief_title>
	<detailed_description>Aim : To test possible neuroprotective effect early high-dose erythropoietin alpha out-of-hospital cardiac arrest ( OHCA ) . Safety , pharmacokinetics estimation potential risk benefit EPO treatment evaluate . Methodology : An open label , pilot , match control study . Following resuscitation mild hypothermia OHCA , participant receive first dose EPO-alpha follow four additional injection within 48 hour ( 40 000 IU intravenously injection ) . Plasma Epo-alpha level measure different time point . Outcome adverse event assess day 28 compare matched-paired control Pilot , open-labelled , match control study perform Nov 2003 May 2004 . As first step , effect high-dose Epo-alpha 20 consecutive patient OHCA successfully resuscitate emergency medical service study . The participant receive first dose Epo-alpha soon possible stable ROSC , follow additional injection every 12h first 48 hour ICU admission ( 40 000 IU intravenously injection ) . Collected data include demographic , clinical characteristic , biological feature , treatment outcome . Severity assess Simplified Acute Physiologic Score 2 ( SAPS2 ) . Mortality neurological outcome record day 28 . All unexpected event assess order detect potential side effect High-dose Epo administration . As second step , outcomes observe among prospective Epo-treated patient compare cohort outcome observe among case-matched historical control . Two match control select Epo-treated patient . Neurological assessment perform admission day day 1 7 , day 14 , 21 28 . Blood sample draw daily day 1 day 7 weekly day 7 day 28 . For pharmacokinetics blood sample draw 2h , 4h , 6h , 8h , 10h , 12h , 24h , 36h , 48h , 72h , 78h , 84h , 96 h first administration Epo-alpha . Intravenous Epo-alpha : First dose soon possible stable return spontaneous circulation ( ROSC ) , follow additional injection every 12 hour first 48 hour . ( 40 000 IU injection )</detailed_description>
	<mesh_term>Heart Arrest</mesh_term>
	<mesh_term>Out-of-Hospital Cardiac Arrest</mesh_term>
	<criteria>Patients OHCA presume cardiac origin Patient 's delay collapse onset cardiopulmonary resuscitation ( CPR , flow ) less 10 minute Patient 's delay onset CPR return spontaneous circulation ( ROSC , low flow ) less 50 minute Patient 's persistent coma Glasgow Coma Scale ( CGS ) less 7 ROSC Patient 's cardiac arrest noncardiac aetiology Patient previous EPO treatment Patient 's pregnancy stage Patient 's evidence rapidly fatal underlying condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Epo-alpha</keyword>
	<keyword>Cardiac arrest</keyword>
	<keyword>Mild hypothermia</keyword>
</DOC>